-- Frost & Sullivan: Comparative efficacy data critical for higher uptake since psoriasis is not considered a life-threatening condition
MOUNTAIN VIEW, Calif., April 30, 2014 /PRNewswire/ -- The market for moderate-to-severe plaque psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of three promising new drug classes: interleukin-17(IL-17) inhibitors, a janus kinase (JAK) inhibitor, and a phosphodiesterase-4 (PDE-4) inhibitor, the last two being oral therapies. These drugs are welcomed additions to the toolbox of therapeutic options available to patients and physicians for an indication historically underserved by novel therapies. The increasingly competitive pipeline is also raising the bar for new entrants.
Recent analysis from Frost & Sullivan's Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market finds the development pipeline for moderate-to-severe psoriasis therapeutics has at least 37 investigational biologic and small molecule drugs in various stages of development. The particularly competitive classes include IL-17 with three candidates in the late stages development and anti-interleukin-23 (IL-23), with five candidates in various stages of development.
For complimentary access to more information on this research, please visit: http://bit.ly/1foOgCh.
"The discovery of the role of tumor necrosis factor alpha (TNFα) in inflammatory diseases led to the commercial launch of several popular TNF blockers," said a Frost & Sullivan Life Sciences analyst. "These highly effective therapies for severe cases of plaque psoriasis are being upstaged by several new drug classes with improved efficacy, safety and tolerability."
While next-generation biopharmaceuticals and novel oral therapies offer superior efficacy and safety, roadblocks, in the form of inadequate clinical differentiation and endorsement of pharmacoeconomic benefits, exist. Hence, pharmaceuticals are lining up numerous head-to-head trials to demonstrate the superiority of their therapies over marketed drugs.
Further, regulator and payer scrutiny of new therapies for chronic plaque psoriasis is increasing, and the bar for approval and reimbursement is significantly higher than it was a decade ago. The availability of several effective and approved TNF blockers for the treatment of the disease places additional pressure on the developers of novel therapies to demonstrate superior profiles in terms of efficacy, safety, tolerability and patient acceptance.
"If the cost and safety profiles are comparable, therapies that offer better patient convenience will be preferred to improve adherence to therapy and prevent relapse," noted the analyst. "Advanced devices and improvements in formulations to reduce the inconvenience of frequent injections could set otherwise similar products apart in the eyes of patients."
Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches, A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market, Analysis of the Global Type 2 Diabetes Therapeutics Market, Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS, and Product and Pipeline Assessment of the Global Orphan Drugs Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.
